BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Soyka M, Franke AG. Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations. World J Psychiatr 2021; 11(9): 543-552 [PMID: 34631459 DOI: 10.5498/wjp.v11.i9.543]
URL: https://www.wjgnet.com/2220-3206/full/v11/i9/543.htm
Number Citing Articles
1
Raul Felipe Palma-Alvarez, Germán Ortega-Hernández, Maria Roch-Santed, Josep Antoni Ramos-Quiroga, Lara Grau-López. Long-acting injectable buprenorphine in the real world: case report on dual disordersJournal of Addictive Diseases 2024; : 1 doi: 10.1080/10550887.2024.2354566
2
Stephen Parkin, Joanne Neale, John Strang. Non-Prescribed Substance Use during the First Month of Treatment by People Receiving Depot Buprenorphine for Opioid Use DisorderSubstance Use & Misuse 2023; 58(13): 1696 doi: 10.1080/10826084.2023.2244064
3
Hannah A. Blair. Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USADrugs & Therapy Perspectives 2024; 40(2): 61 doi: 10.1007/s40267-024-01055-y
4
Tanja Schwarz, Judith Anzenberger, Martin Busch, Gerhard Gmel, Ludwig Kraus, Michael Krausz, Florian Labhart, Maximilian Meyer, Michael P. Schaub, Jean N. Westenberg, Alfred Uhl. Opioid agonist treatment in transition: A cross-country comparison between Austria, Germany and SwitzerlandDrug and Alcohol Dependence 2024; 254: 111036 doi: 10.1016/j.drugalcdep.2023.111036
5
Andrew Burton, Darlene J. DeBona, Michele Handzel, Sarah Kelly-Pisciotti, Min Qiao, Dana Rojek, Nicole M. Acquisto. Surgical removal of extended-release buprenorphine depot due to adverse reactionsThe American Journal of Emergency Medicine 2024; 81: 127 doi: 10.1016/j.ajem.2024.04.047